Valuation: GI Dynamics, Inc.

Market Cap 440K 389K 368K 334K 625K 42.27M 632K 4.41M 1.7M 21.58M 1.65M 1.62M 69.46M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.89M 2.74M 2.48M 4.66M 315M 4.7M 32.85M 12.66M 161M 12.31M 12.05M 517M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 04/08/2025
Director of Finance/CFO 57 31/07/2025
Chief Tech/Sci/R&D Officer - 31/03/2023
Director TitleAgeSince
Director/Board Member - 19/10/2020
Director/Board Member - -
Director/Board Member 69 30/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
28/01/21 Free

Chairman

1,384,483 0.4875%
28/01/21 Free

Chief Executive Officer

11,075,869 3.8998%

Financials

2019 2020
Net sales - -
Net income -17.33M -15.3M -14.47M -13.13M -24.61M -1.66B -24.85M -174M -66.91M -849M -65.09M -63.67M -2.73B -11.14M -9.83M -9.3M -8.43M -15.81M -1.07B -15.97M -112M -42.99M -546M -41.82M -40.91M -1.76B
Net Debt 2.89M 2.55M 2.41M 2.19M 4.1M 277M 4.14M 28.92M 11.15M 141M 10.84M 10.6M 455M 2.84M 2.51M 2.37M 2.15M 4.03M 272M 4.07M 28.44M 10.96M 139M 10.66M 10.43M 448M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock